Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

Trimi vs Vita Bella

Two GLP-1 desks, one scoreboard. We put Trimi and Vita Bella head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 2 · Grade B+

Trimi

Visit Trimi Full brief →
vs
No. 299 · Grade C

Vita Bella

Visit Vita Bella Full brief →

The verdict

Trimi takes this head-to-head.

Trimi scores 89 to 62 on our six-factor Brief Score — A clean, all-in membership desk that publishes one price on both molecules nationwide and hasn't played the teaser-rate game.

That doesn't make Vita Bella a bad call — it's best for readers who want adults wanting compounded semaglutide or tirzepatide inside a broader hormone and wellness membership. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
90
25
Supply Reliability
89
80
Transparency
91
40
Access Breadth
89
84
Clinical Oversight
88
84
Track Record
84
82
TrimiBrief Score 89 · 62Vita Bella

Price, coverage & the tracker

TrimiVita Bella
Brief Score89/100 (B+)62/100 (C)
Semaglutide$196/moFrom $109/mo (starting dose, medication billed separately, compounded)
Tirzepatide$296/moFrom $159/mo (starting dose, plus a separate fee, compounded)
CoverageAll 50 states46 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
On the trackerStableprice stableNewnew to the tracker, no prior reading

Trimi: Membership rate held flat this cycle — both molecules disclosed up front, no first-month teaser.

Vita Bella: New to the tracker on 1 August 2026. The published line reads From $109/mo (starting dose, medication billed separately, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.